Hologic (HOLX) PT, Estimates Raised at Jefferies Post Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Hologic (HOLX) Buy Reiterated a Needham & Company Post Q2 on 'Encouraging' Return to Rev Growth
May 1, 2014 7:15 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following Q2 results which showed an 'encouraging' return to positive revenue growth.
Matson comments, "HOLX's F2Q14 results were well above consensus. Revenue upside was driven... More
Hologic, Inc. (HOLX) Tops Q2 EPS by 4c
April 30, 2014 4:02 PM EDTHologic, Inc. (NASDAQ: HOLX) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $625 million versus the consensus estimate of $609.35 million.
"Second quarter results reflect early progress towards our renewed focus on executional... More
